在前五大重仓股中，窥得儿医药(QDEL.US)位列第一，持仓约826万股，持仓市值约3.77亿美元，占投资组合比例为33.53%，较上季度持仓数量大幅削减28.30%。According to the Securities and Exchange Commission (SEC) disclosure, The Carlyle Group submitted the third quarter (Q3) holdings report (Form 13F) up to September 30, 2024.
According to the Securities and Exchange Commission (SEC) disclosure, The Carlyle Group submitted the third quarter (Q3) holdings report (Form 13F) up to September 30, 2024.
As per statistics, The Carlyle Group had a total holding market value of 0.95 billion USD in the third quarter, a decrease of 9.5% from the previous quarter's 1.05 billion USD. The Carlyle Group added 2 stocks to its holdings portfolio in the third quarter and increased positions in 2 stocks. At the same time, The Carlyle Group reduced holdings in 4 stocks and exited holdings in 7 stocks. The top ten holdings accounted for 95.64% of the total market value.
In the top five heavy-weighted stocks, QuidelOrtho (QDEL.US) ranked first with approximately 8.26 million shares, a holding market value of about 0.377 billion USD, accounting for 33.53% of the investment portfolio, a significant decrease of 28.30% in holdings compared to the previous quarter.
ZoomInfo Technologies (ZI.US) ranked second with around 11.67 million shares, a holding market value of about 0.12 billion USD, accounting for 10.72% of the investment portfolio, a significant decrease of 32.35% in holdings compared to the previous quarter.
Soleno Therapeutics (SLNO.US) ranked third with approximately 2 million shares, a holding market value of about 0.107 billion USD, accounting for 9.54% of the investment portfolio, a decrease of 18.84% in holdings compared to the previous quarter.
Phathom Pharmaceuticals (PHAT.US) ranked fourth, holding approximately 3.5 million shares, with a holding market value of approximately $63.19 million. It accounts for 5.63% of the investment portfolio and the holding quantity remained unchanged from the previous quarter.
Q32 Bio (QTTB.US) ranked fifth, holding approximately 1.1 million shares, with a holding market value of approximately $48.62 million, accounting for 4.33% of the investment portfolio, and the holding quantity remained unchanged from the previous quarter.
In the third quarter, The Carlyle Group initiated positions in Maplebear (CART.US), Forward Air (FWRD.US), Reddit (RDDT.US), while divesting positions in Aon PLC (AON.US), GDS Holdings (GDS.US), Verona Pharma (VRNA.US), Nu Holdings (NU.US), among others.
During this quarter, The Carlyle Group increased shareholding in Seacor Marine (SMHI.US), OnKure Therapeutics (OKUR.US), while divesting positions in Quidelortho, ZoomInfo Technologies, Soleno Therapeutics, and PDD Holdings (PDD.US).
Looking at the changes in holding positions, the top three buys were: Forward Air, Maplebear, Seacor Marine.
The top five sells were: ZoomInfo Technologies, GDS Holdings, Verona Pharma, Aon PLC, Nu Holdings.
